Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 4/20 | 0.45 |
| ▸ | FAP | Q12884 | 3/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 5/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23135343 | 0.85 | XIAP (0.53) | OPRM1XIAPDPP4FAPDPP8 | |
| SCHEMBL23135342 | 0.85 | XIAP (0.53) | OPRM1XIAPDPP4FAPDPP8 | |
| SCHEMBL3808351 | 0.85 | STAT3 (0.48) | OPRM1STAT3 | |
| SCHEMBL4337499 | 0.85 | DPP4 (0.45) | OPRM1XIAPDPP4FAPDPP8 | |
| SCHEMBL4337493 | 0.85 | DPP4 (0.45) | OPRM1XIAPDPP4FAPDPP8 | |
| SCHEMBL3817115 | 0.84 | DPP4 (0.41) | OPRM1XIAPDPP4FAPDPP8 | |
| SCHEMBL29641763 | 0.83 | DPP4 (0.51) | OPRM1XIAPDPP4FAPDPP8 | |
| SCHEMBL29485135 | 0.83 | OPRM1 (0.51) | OPRM1XIAPDPP4FAPDPP8 | |
| SCHEMBL30473075 | 0.83 | DPP4 (0.51) | OPRM1XIAPDPP4FAPDPP8 | |
| SCHEMBL3813773 | 0.83 | PEPD (0.57) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471063-B2 | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | TGM2, TGM3, TGM1 | OPRM1 4413/4885XIAP 1171/4885DPP4 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.